Theodore Henderson, MD, PhD

Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) is a disorder characterized by marked fatigue, exertion induced malaise, cognitive clouding (or brain fog), impaired academic/work performance, disrupted sleep, and joint/muscle pain.

Can mere light become a revolutionary new treatment for traumatic brain injury, posttraumatic stress disorder, depression, stroke, Parkinson disease, and Alzheimer disease?

Studies of the use of ketamine for depression revealed that the agent induces a rapid reduction in depressive symptoms and suicidal ideation in most patients.

Advanced neuroimaging can more accurately diagnose traumatic brain injury and post-traumatic stress disorder than CT or MRI.

Dr. Henderson suggests treating Myalgic Encephalomyelitis/Chronic Fatigue Syndrome with antivirals rather than with antidepressants.

As the Congress, VA, CDC and the Obama Administration address the issue, recent neuroimaging studies point to effective diagnostic tools available for PTSD and TBI — two common conditions among suicide victims.

Neuroimaging studies have shown several neurophysiological substrates for depression: An overview by Theodore Henderson, MD, PhD.

Although inconclusive, late-onset Alzheimer’s Disease could be triggered by infectious pathogens.

Growing evidence indicates that herpes simplex virus 1 may play a role in the development of Alzheimer’s.

Growing evidence boosts support for antiviral therapy in treating chronic fatigue syndrome.